| Summary: | 碩士 === 中原大學 === 應用數學研究所 === 102 === The biggest challenge of National Health Insurance (NHI) in Taiwan is to maintain the
financial balance and provide good quality of medical service because it has to pay necessary
remuneration to medical institutions, but only collect limited inexpensive insurance premium.
The financial status of NHI becomes a concern because its medical budget is increasing year
by year due to some inevitable factors, such as the aging population, expensive medical
research and development and global economic recession. Simply speaking, the premium
income is also far less than medical costs. However, raising premium benchmark or drug
payment adjustment will result in some criticism from the public. Therefore, it is crucial to
avoid unnecessary medical waste and reallocate the limited medical resources appropriately.
This dissertation studies the calculation of sample size in the drug treatment that can be
utilized in the real world to avoid excessive waste of resources and reduce the medical cost in
terms of Cost-Effectiveness Analysis, Incremental Cost-effectiveness Ratio Analysis (ICER)
and Incremental Net Benefit (INB).
Keywords: Cost-Effectiveness Analysis, Incremental Cost-effectiveness Ratio Analysis,
Incremental Net Benefit, significant level, power, confidence interval, sample
size.
|
|---|
